Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Status: | Recruiting |
---|---|
Conditions: | Lymphoma, Neurology |
Therapuetic Areas: | Neurology, Oncology |
Healthy: | No |
Age Range: | 60 - 120 |
Updated: | 1/3/2019 |
Start Date: | May 2012 |
End Date: | March 2019 |
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
Others interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer
cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell
lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab
together with bendamustine and bortezomib is more effective than rituximab and bendamustine,
followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and
lenalidomide in treating previously untreated older patients with mantle cell lymphoma.
ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
Others interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer
cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell
lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab
together with bendamustine and bortezomib is more effective than rituximab and bendamustine,
followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and
lenalidomide in treating previously untreated older patients with mantle cell lymphoma.
OBJECTIVES:
Primary
- To determine whether the addition of bortezomib (RBV) to an induction regimen of
rituximab-bendamustine hydrochloride (RB) improves progression-free survival (PFS)
compared to RB alone in patients ≥ 60 years of age with previously untreated mantle cell
lymphoma.
- To determine whether the addition of lenalidomide to a consolidation regimen of
rituximab following an induction regimen of RB or RBV improves PFS compared to
consolidation rituximab alone in this patient population.
Secondary
- To determine whether the addition of bortezomib to induction therapy improves the
positron emission tomography (PET)-documented complete response (CR) rate compared to RB
alone.
- To determine the objective response rate (ORR) for RB and RBV.
- Among patients who do not have PET-documented CR at the end of induction, to determine
whether the addition of lenalidomide to consolidation therapy improves CR and ORR
compared with rituximab alone.
- To determine overall survival (OS) in the treatment arms.
- To determine safety, with attention to the addition of bortezomib in the induction
regimen and lenalidomide-rituximab (LR) as consolidation therapy.
- To collect paraffin-embedded tissue for creation of tissue microarray.
- To collect and bank serum and blood mononuclear cells for future studies.
- To collect formalin-fixed paraffin-embedded (FFPE) tissue to analyze potential
prognostic factors (Ki-67 proliferation index by immunohistochemistry and correlation
with proposed 5-gene set of proliferation markers analyzed by RNA PCR; SOX 11 expression
by immunohistochemistry; and Micro-RNA levels by microarray).
- Using patient-reported outcomes data, to determine the extent and severity of neuropathy
associated with the addition of bortezomib to induction treatment.
- Using patient-reported outcomes data, to determine the extent and severity of fatigue
associated with the addition of lenalidomide to consolidation treatment.
- To evaluate the effects of the addition of bortezomib and lenalidomide on
patient-reported health-related quality of life.
- To evaluate the effects of bortezomib-related neuropathy on patient-reported
health-related quality of life.
- To evaluate the response of lymphoma-specific symptoms to treatment.
- Using longitudinal patient-reported outcomes data, to describe the trajectory of
lymphoma symptoms, neuropathy, fatigue, and overall health-related quality of life prior
to, during, and following treatment among older adults with MCL.
Tertiary
- To assess the proportion of patients up and down staging when fludeoxyglucose F 18-
(FDG) PET/CT is added to standard Ann Arbor staging.
- To assess the ability of pre-treatment FDG-PET/CT (SUVmax) to predict response rate and
PFS.
- Among patients with interim (post-cycle 3) FDG-PET/CT imaging, to assess the correlation
of interim FDG-PET/CT imaging with response rate and PFS both during induction and
consolidation therapy.
- To assess standard FDG-PET/CT metrics including SUVmax, tumor metabolic burden, total
tumor burden, and association with pathology features (blastoid variant vs other, and
Ki67) in the setting of MCL.
- To assess differences in overall and CR rates when using Deauville vs International
Harmonization Project FDG-PET/CT interpretation criteria.
- To determine whether there is a correlation between FDG-PET/CT response and residual
disease assessment by molecular and/or flow cytometric techniques.
- To determine whether the number of malignant cells in circulation predict the number of
cells in marrow.
- To determine whether the number of malignant cells in circulation/in marrow at the end
of induction correlate with CR and 2-year PFS.
- To determine whether there is a higher rate of minimal residual disease (MRD) negativity
among patients randomized to RBV as compared with RB, and among patients treated with LR
maintenance compared with rituximab.
- To compare the two methods of MRD detection - molecular techniques and flow cytometry -
as prognostic markers for outcome.
OUTLINE: This is a multicenter study. Patients are stratified according to mantle cell
lymphoma International Prognostic Index risk score (low vs intermediate vs high). Patients
are randomized to 1 of 4 treatment arms.
- Arm A: Patients receive induction therapy comprising rituximab IV on day 1 and
bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4
weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm E: Patients receive consolidation therapy comprising rituximab IV on day 1.
Courses repeat every 8 weeks for 2 years in the absence of disease progression or
unacceptable toxicity.
- Arm B: Patients receive induction therapy comprising bortezomib IV or subcutaneously
(SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in
arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease
progression or unacceptable toxicity.
- Arm F: Patients receive consolidation therapy comprising rituximab IV on day 1.
Courses repeat every 8 weeks for 2 years in the absence of disease progression or
unacceptable toxicity.
- Arm C: Patients receive induction therapy comprising rituximab and bendamustine
hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the
absence of disease progression or unacceptable toxicity.
- Arm G: Patients receive consolidation therapy comprising lenalidomide orally (PO)
daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the
absence of disease progression or unacceptable toxicity.
- Arm D: Patients receive bortezomib, rituximab, and bendamustine hydrochloride as
patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of
disease progression or unacceptable toxicity.
- Arm H: Patients receive consolidation therapy comprising lenalidomide PO daily on
days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence
of disease progression or unacceptable toxicity.
Patients may undergo blood and bone marrow sample collection at baseline and during treatment
for correlative studies.
Patients complete the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym), the
FACT/GOG-Neurotoxicity scale (FACT/GOG-Ntx), FACT-Fatigue, and FACT-General questionnaires at
baseline and periodically during study and follow up.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually for 10 years.
Primary
- To determine whether the addition of bortezomib (RBV) to an induction regimen of
rituximab-bendamustine hydrochloride (RB) improves progression-free survival (PFS)
compared to RB alone in patients ≥ 60 years of age with previously untreated mantle cell
lymphoma.
- To determine whether the addition of lenalidomide to a consolidation regimen of
rituximab following an induction regimen of RB or RBV improves PFS compared to
consolidation rituximab alone in this patient population.
Secondary
- To determine whether the addition of bortezomib to induction therapy improves the
positron emission tomography (PET)-documented complete response (CR) rate compared to RB
alone.
- To determine the objective response rate (ORR) for RB and RBV.
- Among patients who do not have PET-documented CR at the end of induction, to determine
whether the addition of lenalidomide to consolidation therapy improves CR and ORR
compared with rituximab alone.
- To determine overall survival (OS) in the treatment arms.
- To determine safety, with attention to the addition of bortezomib in the induction
regimen and lenalidomide-rituximab (LR) as consolidation therapy.
- To collect paraffin-embedded tissue for creation of tissue microarray.
- To collect and bank serum and blood mononuclear cells for future studies.
- To collect formalin-fixed paraffin-embedded (FFPE) tissue to analyze potential
prognostic factors (Ki-67 proliferation index by immunohistochemistry and correlation
with proposed 5-gene set of proliferation markers analyzed by RNA PCR; SOX 11 expression
by immunohistochemistry; and Micro-RNA levels by microarray).
- Using patient-reported outcomes data, to determine the extent and severity of neuropathy
associated with the addition of bortezomib to induction treatment.
- Using patient-reported outcomes data, to determine the extent and severity of fatigue
associated with the addition of lenalidomide to consolidation treatment.
- To evaluate the effects of the addition of bortezomib and lenalidomide on
patient-reported health-related quality of life.
- To evaluate the effects of bortezomib-related neuropathy on patient-reported
health-related quality of life.
- To evaluate the response of lymphoma-specific symptoms to treatment.
- Using longitudinal patient-reported outcomes data, to describe the trajectory of
lymphoma symptoms, neuropathy, fatigue, and overall health-related quality of life prior
to, during, and following treatment among older adults with MCL.
Tertiary
- To assess the proportion of patients up and down staging when fludeoxyglucose F 18-
(FDG) PET/CT is added to standard Ann Arbor staging.
- To assess the ability of pre-treatment FDG-PET/CT (SUVmax) to predict response rate and
PFS.
- Among patients with interim (post-cycle 3) FDG-PET/CT imaging, to assess the correlation
of interim FDG-PET/CT imaging with response rate and PFS both during induction and
consolidation therapy.
- To assess standard FDG-PET/CT metrics including SUVmax, tumor metabolic burden, total
tumor burden, and association with pathology features (blastoid variant vs other, and
Ki67) in the setting of MCL.
- To assess differences in overall and CR rates when using Deauville vs International
Harmonization Project FDG-PET/CT interpretation criteria.
- To determine whether there is a correlation between FDG-PET/CT response and residual
disease assessment by molecular and/or flow cytometric techniques.
- To determine whether the number of malignant cells in circulation predict the number of
cells in marrow.
- To determine whether the number of malignant cells in circulation/in marrow at the end
of induction correlate with CR and 2-year PFS.
- To determine whether there is a higher rate of minimal residual disease (MRD) negativity
among patients randomized to RBV as compared with RB, and among patients treated with LR
maintenance compared with rituximab.
- To compare the two methods of MRD detection - molecular techniques and flow cytometry -
as prognostic markers for outcome.
OUTLINE: This is a multicenter study. Patients are stratified according to mantle cell
lymphoma International Prognostic Index risk score (low vs intermediate vs high). Patients
are randomized to 1 of 4 treatment arms.
- Arm A: Patients receive induction therapy comprising rituximab IV on day 1 and
bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4
weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm E: Patients receive consolidation therapy comprising rituximab IV on day 1.
Courses repeat every 8 weeks for 2 years in the absence of disease progression or
unacceptable toxicity.
- Arm B: Patients receive induction therapy comprising bortezomib IV or subcutaneously
(SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in
arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease
progression or unacceptable toxicity.
- Arm F: Patients receive consolidation therapy comprising rituximab IV on day 1.
Courses repeat every 8 weeks for 2 years in the absence of disease progression or
unacceptable toxicity.
- Arm C: Patients receive induction therapy comprising rituximab and bendamustine
hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the
absence of disease progression or unacceptable toxicity.
- Arm G: Patients receive consolidation therapy comprising lenalidomide orally (PO)
daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the
absence of disease progression or unacceptable toxicity.
- Arm D: Patients receive bortezomib, rituximab, and bendamustine hydrochloride as
patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of
disease progression or unacceptable toxicity.
- Arm H: Patients receive consolidation therapy comprising lenalidomide PO daily on
days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence
of disease progression or unacceptable toxicity.
Patients may undergo blood and bone marrow sample collection at baseline and during treatment
for correlative studies.
Patients complete the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym), the
FACT/GOG-Neurotoxicity scale (FACT/GOG-Ntx), FACT-Fatigue, and FACT-General questionnaires at
baseline and periodically during study and follow up.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually for 10 years.
DISEASE CHARACTERISTICS:
- Histologically confirmed untreated mantle cell lymphoma (MCL), with documented cyclin
D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in
situ hybridization (FISH)
- Patients must have at least one objective measurable disease parameter
- Abnormal PET scans will not constitute evaluable disease, unless verified by CT
scan or other appropriate imaging
- Measurable disease in the liver is required if the liver is the only site of
lymphoma
- Patient must have no CNS involvement
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- ANC ≥ 1,500/mcL (1.5 x 10^9/L)*
- Platelets ≥ 100,000/mcL (100 x 10^9/L)* NOTE: *Unless due to marrow involvement.
- AST/ALT ≤ 2 times upper limit of normal (ULN)
- Bilirubin ≤ 2 times ULN
- Calculated creatinine clearance by Cockroft-Gault formula ≥ 30 mL/min
- Women (sexually mature female) must not be pregnant or breast-feeding
- Negative pregnancy test
- Women of childbearing potential and sexually active males use an accepted and
effective method of contraception
- Men must agree to use a latex condom during sexual contact with a female of
child-bearing potential, even if they have had a successful vasectomy
- All patients must be counseled at a minimum of every 28 days about pregnancy
precautions and risks of fetal exposure
- No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in
situ cervical carcinoma, or any surgically or radiation-cured malignancy continuously
disease free for ≥ 5 years so as not to interfere with interpretation of radiographic
response
- Patient agrees that if randomized to Arms C or D, and proceed onto Arms G or H, they
must register into the mandatory RevAssist® program, and be willing and able to comply
with the requirements of RevAssist®
- Patients must have no medical contra-indications to, and be willing to take, deep
vein thrombosis (DVT) prophylaxis as all patients registering to the
lenalidomide/rituximab Arms G and H will be required to have DVT prophylaxis
- Patients randomized to Arms G or H who have a history of a thrombotic
vascular event will be required to have therapeutic doses of low-molecular
weight heparin or warfarin to maintain an INR between 2.0 - 3.0
- Patients on Arms G and H without a history of a thromboembolic event are
required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis
- Patients who are unable to tolerate aspirin should receive low
molecular weight heparin therapy or warfarin treatment
- Women must agree to abstain from donating blood during study participation and
for at least 28 days after discontinuation from protocol treatment
- Males must agree to abstain from donating blood, semen, or sperm during study
participation and for at least 28 days after discontinuation from protocol
treatment
- HIV-positive patients are not excluded but, to enroll, must meet all of the below
criteria:
- HIV is sensitive to antiretroviral therapy
- Must be willing to take effective antiretroviral therapy, if indicated
- No history of CD4 prior to or at the time of lymphoma diagnosis < 300 cells/mm³
- No history of AIDS-defining conditions
- If on antiretroviral therapy, must not be taking zidovudine or stavudine
- Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP)
during therapy and until at least 2 months following the completion of therapy or
until the CD4 cells recover to over 250 cells/mm³, whichever occurs later
- Patients must not have grade 2 or greater peripheral neuropathy
- Patients must not have NYHA Class III or IV heart failure, uncontrolled angina, severe
uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia
- Patients must not have hypersensitivity to bortezomib, boron, or mannitol
- Patients must not have a serious medical or psychiatric illness likely to interfere
with study participation
PRIOR CONCURRENT THERAPY:
- No prior therapy for MCL, except < 1 week of steroid therapy for symptom control
- HIV-positive patients are not excluded, but to enroll, must meet all of the below
criteria:
- Must be willing to take effective antiretroviral therapy if indicated
- If on antiretroviral therapy, must not be taking zidovudine or stavudine
- Patients must not be participating in any other clinical trial or taking any other
experimental medications within 14 days prior to registration
We found this trial at
426
sites
Westlake, Ohio 44145
Principal Investigator: Paolo F. Caimi
Phone: 800-641-2422
Click here to add this to my saved trials
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Andrew M. Evens
Phone: 617-636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-4673
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Raymond S. Lord
Phone: 269-373-7458
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Raymond S. Lord
Phone: 269-373-7458
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
701 Doctors Dr
Kinston, North Carolina 28504
Kinston, North Carolina 28504
(252) 559-2200
Principal Investigator: Peter R. Watson
Phone: 252-559-2200
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
Click here to add this to my saved trials
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
New York, New York 10029
(212) 241-6500
Principal Investigator: Samir S. Parekh
Phone: 212-824-7320
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Jonathan W. Friedberg
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
206-667-4584
Principal Investigator: Brian G. Till
Phone: 800-422-6237
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Brian G. Till
Phone: 800-422-6237
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
Spokane, Washington 99202
(509) 228-1000
Principal Investigator: Brian G. Till
Phone: 800-422-6237
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Jennifer E. Payne
Phone: 330-375-6101
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
Ames, Iowa 50010
(866) 972-5477
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Click here to add this to my saved trials
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
Michigan Cancer Research Consortium Community Clinical Oncology Program The Community Clinical Oncology Program (CCOP) is...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-4673
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Hamied R. Rezazadeh
Phone: 877-405-6866
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 626-564-3455
Click here to add this to my saved trials
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Suman B. Rao
Phone: 443-777-7364
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
155 5th St NE
Barberton, Ohio 44203
Barberton, Ohio 44203
(330) 615-3000
Principal Investigator: Jennifer E. Payne
Phone: 330-375-6101
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Robert V. Emmons
Phone: 888-562-4763
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Gilbert D. Padula
Phone: 616-685-5225
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Anjali S. Advani
Phone: 866-223-8100
Click here to add this to my saved trials
1600 Albany Street
Beech Grove, Indiana 46107
Beech Grove, Indiana 46107
(317) 787–3311
Saint Francis Hospital and Health Centers St. Francis Hospital and Health Centers is a general...
Click here to add this to my saved trials
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
Click here to add this to my saved trials
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
90 Poly Drive, Suite 2
Billings, Montana 59101
Billings, Montana 59101
(406) 237-5460
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Montana Cancer Consortium CCOP The Montana Cancer Consortium is a nonprofit organization whose mission is...
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-4673
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Click here to add this to my saved trials
Bozeman Deaconess Cancer Center Bozeman Deaconess Cancer Center provides the latest cancer technologies and treatment...
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Ramakrishna Battini
Phone: 718-904-2730
Click here to add this to my saved trials
1300 Morris Park Ave
Bronx, New York 10461
Bronx, New York 10461
(718) 430-2000
Principal Investigator: Ramakrishna Battini
Phone: 718-904-2730
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Joseph W. Leach
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: James L. Wade
Phone: 217-876-4740
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: James L. Wade
Phone: 217-876-4740
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
Click here to add this to my saved trials
Cedar Rapids, Iowa 52403
Principal Investigator: Deborah W. Wilbur
Phone: 319-363-2690
Click here to add this to my saved trials
Click here to add this to my saved trials
Cedar Rapids, Iowa 52403
Principal Investigator: Deborah W. Wilbur
Phone: 319-363-2690
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Michael E. Williams
Phone: 434-243-6143
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Click here to add this to my saved trials
Saint Luke's Hospital St. Luke's Hospital, located in Chesterfield, Missouri, is a regional healthcare provider...
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 864-6000
Principal Investigator: Luis D. Sumoza Benitez
Phone: 312-864-6000
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
Click here to add this to my saved trials
Click here to add this to my saved trials
Hematology and Oncology Associates Northwestern Medical Faculty Foundation (the Foundation) is a premier, multi-specialty physician...
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Jane N. Winter
Phone: 312-695-1301
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
Cincinnati, Ohio 45267
(513) 556-6000
Principal Investigator: Stephen C. Medlin
Phone: 513-558-4553
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45230
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45211
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Alison K. Conlin
Phone: 503-215-6412
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
Cleveland, Ohio 44109
(216) 778-7800
Principal Investigator: Bruce J. Averbook
Phone: 216-778-8526
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Anjali S. Advani
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Paolo F. Caimi
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Anjali S. Advani
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: James N. Atkins
Phone: 919-580-0000
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Click here to add this to my saved trials
1 Hospital Dr
Columbia, Missouri 65212
Columbia, Missouri 65212
(573) 882-2100
Principal Investigator: Donald C. Doll
Phone: 573-882-7440
University of Missouri-Ellis Fischel Ellis Fischel Cancer Center's team of physician specialists and other trained...
Click here to add this to my saved trials
300 W 10th Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(800) 293-5066
Principal Investigator: Kristie A. Blum
Phone: 800-293-5066
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center...
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Joseph W. Leach
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Crestview Hills, Kentucky 41017
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
Click here to add this to my saved trials
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 800-446-5532
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Edward J. Gorak
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
1 Wyoming St,
Dayton, Ohio 45409
Dayton, Ohio 45409
(937) 208-8000
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
Click here to add this to my saved trials
Grandview Hospital You'll feel like part of our family when you visit Grandview Medical Center...
Click here to add this to my saved trials
2222 Philadelphia Dr
Dayton, Ohio 45406
Dayton, Ohio 45406
(937) 734-2612
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Good Samaritan Hospital - Dayton Good Samaritan Hospital (GSH) is passionate about providing the most...
Click here to add this to my saved trials